(Finance) – The Shareholders’ Meeting of Fine Foods & Pharmaceuticals approved the financial statements as at 31 December 2023, as well as the Management Report of the Board of Directors and presented the Consolidated Financial Statements of the Fine Foods Group, as well as the Consolidated Non-Financial Statement, referring to the same financial year.
As for the destination of the operating result, the Assembly resolved to cover the loss entirely through the use of the “Merger surplus reserve”.
The shareholders also approved the distribution of a unitary dividend in the amount of Euro 0.12 gross of legal withholdings where applicable, for each of the Company’s shares in circulation to the shareholders holding shares entitled to payment on the envisaged date of enjoyment, for a maximum total amount of Euro 3,300,000.00, using the “Merger surplus reserve”.
The Assembly also provided for the appointment of the new Board of Directors and the new Board of Auditors.
The Board of Directors, which met following the Assembly, granted operational delegations to the President Marco Francesco Eigenmann and the Director Giorgio Ferraris, appointing him Managing Director and CEO.